ANNAPOLIS, Md., Sept. 16, 2016 /PRNewswire/ -- PharmAthene, Inc.
(NYSE MKT: PIP), a biodefense company developing medical
countermeasures against anthrax, today announced it has received a
series of payments from SIGA Technologies, Inc. totaling
$90 million over the past
month. Combined with $25
million in previous payments, PharmAthene has now received a
total of $115 million plus
$6.6 million of interest in partial
payment of the SIGA judgement. Under the approved reorganization
plan, SIGA has until November 30,
2016 to pay the remaining balance of $93.7 million plus interest.
About PharmAthene
PharmAthene is a biodefense company engaged in the development
of next generation medical countermeasures against biological
threats. The Company's development portfolio includes a next
generation anthrax vaccine that is intended to improve protection
while having favorable dosage and storage requirements compared to
other anthrax vaccines.
Forward-Looking Statement Disclaimer
Except for the historical information presented herein, matters
discussed may constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
that are subject to certain risks and uncertainties that could
cause actual results to differ materially from any future results,
performance or achievements expressed or implied by such
statements. Statements that are not historical facts, including
statements preceded by, followed by, or that include the words
"potential"; "believe"; "anticipate"; "intend"; "plan"; "expect";
"estimate"; "could"; "may"; "should"; "will"; "project"; or similar
statements are forward-looking statements. Risks and uncertainties
include risks relating to the challenges facing a biotechnology
company involved in the development of vaccines and others detailed
from time to time in PharmAthene's Forms 10-K and 10-Q under the
caption "Risk Factors" and in its other reports filed with the U.S.
Securities and Exchange Commission. PharmAthene disclaims any
intent or obligation to update these forward-looking statements
other than as required by law. Copies of PharmAthene's public
disclosure filings are available on our website under the investor
relations tab at www.PharmAthene.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/pharmathene-announces-receipt-of-payments-from-siga-300329363.html
SOURCE PharmAthene, Inc.